HSG

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Wuxi Gongwang inductive sensor developer offering high-precision, oil and dust-resistant products for various industries, including aerospace, automotive, medical care, and more.

Taiyi Guanjia is a company that combines technology and medical health innovation, aiming to enhance the insurance industry and create a robust medical and health ecosystem.

Spear Bio is a biotechnology company established in 2021 and located in Weston, Massachusetts. The company specializes in ultrasensitive protein detection technology, which provides significant advantages in the healthcare sector. Its innovations support self-testing and telemedicine-based diagnostics by enabling the quantification of minute protein biomarkers from samples collected at home. This approach allows clinicians to achieve ultrasensitive detection using small sample volumes, seamlessly integrating into existing workflows for sample collection, processing, and analysis.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Noah Medical is a manufacturer of medical robotic devices aimed at enhancing the diagnosis and treatment of patients in various healthcare settings. The company's innovative devices facilitate early diagnoses and treatments, particularly in advanced clinical environments. By enabling hospitals to address medical issues promptly, Noah Medical's technology contributes to improved patient outcomes and minimizes scarring associated with procedures.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.

Founded in 2012, Vivolight is a medical device company incubated and supported by Xi'an Institute of Optics and Precision Mechanics of Chinese Academy of Sciences. We are headquartered in Shenzhen and have established an R&D center in Xi’an. Rooted in the field of medical laser technology, we are committed to the independent development, global innovation and independent manufacturing of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser by leveraging the world-leading photoelectric technology and combining medicine and engineering. In April 2020, our self-developed optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, our innovative Multimodality OCT System was approved by NMPA. It is the first Multimodality OCT System in the field of coronary artery OCT that has been approved for clinical application. In the field of interventional laser therapy, we have multiple products that have entered the phase of pre-clinical study.

EagleChip is a chip design company that specializes in the development and design of Field Programmable Gate Arrays (FPGAs). It focuses on research and development, creating tailored electronic design automation (EDA) toolchains that cater to various industries. These industries include communications, data centers, industrial control, consumer electronics, smart vehicles, video processing, and medical electronics. EagleChip aims to provide high-quality FPGA chip solutions to meet the specific needs of its customers, ensuring a reliable domestic supply in the competitive semiconductor market.

Spectrum Medical is a clinical mass spectrometry product platform that promotes clinical mass spectrometry detection technology to the general public. It has an experienced research and development, operations, and sales team, a standardized GMP production workshop, extensive experience in laboratory construction, and a mature laboratory management system. It provides with complete supporting kits in addition to mastering the core mass spectrometry hardware manufacturing technology and equipment integration development capabilities (maternal and child genetics, nutritional levels, therapeutic drug testing, metabolic monitoring, etc.).

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Scientech Medical engages in the research, development, and manufacturing of interventional medical devices.

SceneRay Co. Ltd, based in Singapore Industrial Park, Suzhou, China, specializes in the design, development, and distribution of neuromodulation devices, particularly focusing on brain pacemakers. The company’s core team comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, both in China and internationally. SceneRay's product offerings include a dual-channel implantable pulse generator kit designed for deep brain stimulation, which provides therapeutic electric stimulation to address issues related to brain damage. Committed to innovation, SceneRay holds numerous patents and strives to deliver high-quality, effective treatments for patients.

Vico Medical, established in 2018 and based in Wuhan, China, specializes in the development and production of medical devices aimed at treating cardiovascular and cerebrovascular diseases. The company offers a range of products, including atrial shunts, puncture systems, and occluders for patent foramen ovale, along with delivery systems and other related devices. Vico Medical focuses on providing innovative intervention treatment solutions for structural cardiovascular issues, contributing to the reduction of stroke and heart-related disease incidents.

SyMap Medical focuses on developing and manufacturing a proprietary catheter-based system for renal mapping and ablation, specifically aimed at treating hypertension and various other serious conditions, including heart failure, arrhythmia, and renal failure. The company's core technology platform is based on radiofrequency (RF) ablation, which is integral to its approach in renal nerve mapping and selective ablation. This innovative medical device is designed to enhance treatment options for patients suffering from these significant health issues.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company offers a comprehensive range of biological heart valves, focusing on minimally invasive solutions that enhance patient outcomes. Utilizing cutting-edge technologies, including anti-calcification, dry presentation, and leaflet thinning, KingstronBio aims to deliver innovative and effective products to the medical community, thereby addressing critical needs in cardiovascular care.

Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

Suzhou Xinqing Medical Technology Co., Ltd., founded in 2017 by Dr. Xu Bozhen, focuses on the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular illnesses. The company specializes in creating short-term to medium-term ventricular assist devices that leverage advanced fluid mechanics and magnetic suspension technology. These innovations allow the devices to be compatible with various blood types, thereby reducing the risk of incompatibility for patients. With a team of leading experts in artificial heart engineering, the company has successfully developed an artificial heart that holds independent intellectual property rights, positioning itself as a key player in the medical technology sector.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Eighteeth focuses on the research and production of dental instruments. Eighteeth has 14 product categories including endo motor, apex locator, ultrasonic scaler, curing light, X-Ray unit, intraoral sensor, intraoral scanner, and owns 110 authorized patents.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Benchling, Inc. is a cloud-based informatics company that provides a comprehensive platform tailored for life sciences research and development. Its flagship offering allows scientists to design, share, and document experiments through an integrated interface, enhancing collaboration and efficiency. The platform includes Benchling Insights, which enables users to query and visualize structured data, and a Bioregistry system for managing biological entity registrations and inventory such as plasmids and cell strains. Benchling's solutions support a variety of applications, including antibodies, cell therapy, gene therapy, and vaccines, catering to the needs of scientists in biotech, pharmaceutical, academic, and government sectors. Founded in 2012 and headquartered in San Francisco, Benchling aims to streamline the research process from discovery to bioprocessing, facilitating critical R&D decisions with its unified software suite.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

YuanHua Zhineng specializes in sophisticated medical and intelligent service robots. The company provides a robot system for orthopedic surgery that can help surgeons with a variety of procedures, including spine, knee/hip replacement, trauma, and knee/hip replacement.

Neuracle is a prominent enterprise in China's neuroscience sector, specializing in neural monitoring and diagnostic technology. Leveraging advanced brain-machine interface technology developed in collaboration with Tsinghua University, Neuracle focuses on innovative research across neuroscience, psychology, and neuroengineering. The company provides comprehensive solutions for the diagnosis, treatment, and rehabilitation of clinical neurological diseases. Its product offerings include digital electroencephalographs that allow healthcare institutions to monitor patients' brain bioelectricity levels and facilitate accurate diagnoses of neural conditions. Neuracle's contributions span various fields, including clinical medicine and management marketing, and the company's research and development efforts have garnered recognition from experts in neuroscience and clinical medicine both domestically and internationally.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Babycare is an e-commerce platform providing products for new parents and children. The company specializes in the design, research, and development of mother-baby products. Its products are based on recommendations by a series of research and experiments regarding orthopedic development of babies. One of its products is the infant waist carrier, which is crafted to improve the comfortability of infants and prevent from bowleg posturing which hinders blood circulation. The company is committed to achieving the aspiration of being product designers and baby caretakers. The company was founded in 2014 and is headquartered in Shanghai, China.

WeDoctor is a prominent medical health technology platform founded in 2010 by Liao Jieyuan and his team. The company aims to enhance access to healthcare by leveraging technology to provide a comprehensive range of services. Its mobile application allows users to connect with hospitals and doctors, schedule appointments, and access medical advice and ratings for healthcare providers. By integrating both online and offline medical services, WeDoctor aspires to serve as a health management organization, facilitating improved healthcare experiences for millions of families. The platform emphasizes a user-friendly approach to healthcare, making essential medical services readily available and efficient.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

AccuMedical is a full-line product company in the field of neurological intervention, headquartered in Beijing with an R&D center located in California. It develops and produces medical device products for the treatment of aneurysms, preventing, and treating bleeding diseases caused by the rupture of vascular aneurysms.

SiBionics is a medtech company based in Shenzhen, China, focused on the research and development of active implantable medical devices and medical artificial intelligence. The company specializes in creating innovative solutions for various health conditions, including retinitis pigmentosa, diabetes, cardiovascular diseases, and gastrointestinal tumors. SiBionics develops artificial intelligence technologies for medical imaging and implantable devices, including retinal electrical stimulators and continuous glucose monitors. Their work also encompasses health management, disease screening, and diagnostics, using approaches such as visual coding, medical imaging AI, and big data analytics to enhance patient care and address chronic diseases. Through these advancements, SiBionics aims to provide cost-effective products that improve long-term monitoring and treatment options in the medical field.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company focused on the research, development, and manufacturing of antibody-based therapeutics. Established in 2019 and headquartered in Suzhou, China, the company operates additional facilities in Shanghai, Hangzhou, Beijing, Waltham, and Princeton. Transcenta's integrated approach encompasses the discovery and development of innovative antibodies aimed at addressing various medical conditions, particularly in oncology and specific non-oncology areas such as bone and kidney disorders. The company is currently advancing nine therapeutic antibody molecules through clinical development, underscoring its commitment to improving patient outcomes. Transcenta was formed through the merger of HJB and MabSpace Biosciences, positioning it as a significant player in the global biopharmaceutical landscape.

Eko.ai Pte. Ltd. is a Singapore-based company that specializes in artificial intelligence software aimed at the early detection and treatment of heart disease. Founded in 2017, the company focuses on democratizing echocardiography and ultrasound imaging to enhance cardiovascular risk assessment. Eko.ai employs machine learning to automate processes, providing research teams with fully classified, machine learning-ready databases and a variety of tools, including segmentation and validation models. By collaborating with clinician scientists, sonographers, and deep learning experts, Eko.ai serves laboratories worldwide, aiming to improve productivity and patient outcomes within hospital systems.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Babycare is an e-commerce platform providing products for new parents and children. The company specializes in the design, research, and development of mother-baby products. Its products are based on recommendations by a series of research and experiments regarding orthopedic development of babies. One of its products is the infant waist carrier, which is crafted to improve the comfortability of infants and prevent from bowleg posturing which hinders blood circulation. The company is committed to achieving the aspiration of being product designers and baby caretakers. The company was founded in 2014 and is headquartered in Shanghai, China.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company focused on the research, development, and manufacturing of antibody-based therapeutics. Established in 2019 and headquartered in Suzhou, China, the company operates additional facilities in Shanghai, Hangzhou, Beijing, Waltham, and Princeton. Transcenta's integrated approach encompasses the discovery and development of innovative antibodies aimed at addressing various medical conditions, particularly in oncology and specific non-oncology areas such as bone and kidney disorders. The company is currently advancing nine therapeutic antibody molecules through clinical development, underscoring its commitment to improving patient outcomes. Transcenta was formed through the merger of HJB and MabSpace Biosciences, positioning it as a significant player in the global biopharmaceutical landscape.

Medtrum Technologies Inc., established in 2008, specializes in developing and delivering medical devices for diabetes management. Its product portfolio includes the A6 TouchCare System, a tubing-free semi-closed loop insulin management system that integrates an insulin patch pump and continuous glucose monitoring system (CGMS), offering predictive low glucose suspend. The S6 EasySense is a waterproof, disposable CGM system with a hair-like sensor, providing real-time glucose readings for a week. The P6 EasyPatch is a disposable insulin pump with adjustable basal rates and bolus on demand functionality. Medtrum's cloud-based healthcare system, comprising the Medtrum EasyTouch mobile app and EasyView web portal, consolidates patient data for self-management, family support, and healthcare provider access. The company, headquartered in Shanghai, China, also operates in Düsseldorf, Germany; Hong Kong; and Watford, United Kingdom.

Infervision is an artificial intelligence company based in Beijing that specializes in medical imaging diagnosis. Utilizing deep learning technology and computer vision, Infervision develops innovative solutions to assist in the diagnosis of cancers and other medical conditions. The company launched the world's first artificial intelligence precise healthcare platform and has introduced intelligent X-ray and CT diagnosis products, which are currently undergoing trials in several prominent hospitals in China. Infervision collaborates closely with top medical institutions, fostering strong partnerships with nearly 20 Tertiary Grade A hospitals, including Peking Union Medical College Hospital and Tongji Medical College. This collaboration aims to enhance the integration of medical data, technology, and application scenarios, ultimately providing more accurate and efficient diagnostic tools for healthcare professionals. Through its research and development efforts, Infervision is committed to advancing the field of artificial intelligence in healthcare, thereby improving patient outcomes and reducing costs.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with a lab in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the tumor microenvironment using fresh, unmodified human tumor fragments and autologous blood samples, enabling oncologists and drug developers to test individual tumors and predict patient response to treatments with higher accuracy. Farcast's mission is to illuminate personalized treatment paths for cancer patients by providing precise, patient-specific data.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Infervision is an artificial intelligence company based in Beijing that specializes in medical imaging diagnosis. Utilizing deep learning technology and computer vision, Infervision develops innovative solutions to assist in the diagnosis of cancers and other medical conditions. The company launched the world's first artificial intelligence precise healthcare platform and has introduced intelligent X-ray and CT diagnosis products, which are currently undergoing trials in several prominent hospitals in China. Infervision collaborates closely with top medical institutions, fostering strong partnerships with nearly 20 Tertiary Grade A hospitals, including Peking Union Medical College Hospital and Tongji Medical College. This collaboration aims to enhance the integration of medical data, technology, and application scenarios, ultimately providing more accurate and efficient diagnostic tools for healthcare professionals. Through its research and development efforts, Infervision is committed to advancing the field of artificial intelligence in healthcare, thereby improving patient outcomes and reducing costs.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.

Infervision is an artificial intelligence company based in Beijing that specializes in medical imaging diagnosis. Utilizing deep learning technology and computer vision, Infervision develops innovative solutions to assist in the diagnosis of cancers and other medical conditions. The company launched the world's first artificial intelligence precise healthcare platform and has introduced intelligent X-ray and CT diagnosis products, which are currently undergoing trials in several prominent hospitals in China. Infervision collaborates closely with top medical institutions, fostering strong partnerships with nearly 20 Tertiary Grade A hospitals, including Peking Union Medical College Hospital and Tongji Medical College. This collaboration aims to enhance the integration of medical data, technology, and application scenarios, ultimately providing more accurate and efficient diagnostic tools for healthcare professionals. Through its research and development efforts, Infervision is committed to advancing the field of artificial intelligence in healthcare, thereby improving patient outcomes and reducing costs.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with a lab in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the tumor microenvironment using fresh, unmodified human tumor fragments and autologous blood samples, enabling oncologists and drug developers to test individual tumors and predict patient response to treatments with higher accuracy. Farcast's mission is to illuminate personalized treatment paths for cancer patients by providing precise, patient-specific data.

Health 724 is a health service provider based on users, health managers, and health products. They offer direct supply of health products to users who are concerned about their own and their families' health, as well as customized health solutions.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.

Celon Laboratories Pvt. Ltd., established in 2001 and headquartered in Hyderabad, India, is a specialty generics company focused on research, development, manufacturing, and marketing of pharmaceutical products. Its portfolio includes branded and generic formulations in the niche therapy areas of oncology and critical care, serving markets in Asia, Africa, Latin America, and Eastern Europe. The company's product range comprises various dosage forms such as tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. Additionally, Celon offers contract research manufacturing services, including formulation development, lyophilization cycle development, quality control testing, stability studies, and regulatory support. As of 2020, Celon operates as a subsidiary of ZNZ Pharma 2 Ltd.

SyMap Medical focuses on developing and manufacturing a proprietary catheter-based system for renal mapping and ablation, specifically aimed at treating hypertension and various other serious conditions, including heart failure, arrhythmia, and renal failure. The company's core technology platform is based on radiofrequency (RF) ablation, which is integral to its approach in renal nerve mapping and selective ablation. This innovative medical device is designed to enhance treatment options for patients suffering from these significant health issues.

EndoChoice is a medical technology company specializing in the design and commercialization of products and services for gastrointestinal (GI) care. Headquartered in Alpharetta, Georgia, EndoChoice offers a comprehensive range of products, including single-use devices, infection control solutions, diagnostics, and advanced imaging systems. The company's proprietary product portfolio features the Full Spectrum Endoscopy™ System, known as Fuse™, which includes colonoscopes and gastroscopes equipped with multiple imagers. This innovative system enables physicians to achieve a 330-degree field of view, significantly improving the detection of polyps compared to traditional endoscopes. With a direct sales organization serving over 2,000 customers in the United States and partnerships with 34 distributors globally, EndoChoice has established a strong presence in the market. Founded in 2008, the company experienced rapid growth and was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. before its acquisition by Boston Scientific in 2016.

B-Lite is provides lightweight breast implants. B-Lite implants reduce gravitational stress on the breast soft-tissue, as well as retain shape and form in the long term.

Whale Imaging Inc. manufactures medical imaging devices, specializing in surgical imaging systems and ultrasound systems. Its product line includes G-Arm products, such as the G-Arm B6 Duo and G-Arm GXi 2, as well as portable ultrasound devices like the Lambda P9 and Sigma P5. In addition to manufacturing, Whale Imaging offers training, preventative maintenance, and support services to ensure optimal use of its products. Founded in 1998, the company is headquartered in Beijing's hi-tech enterprise zone, with research and development facilities being established in Boston, Massachusetts. Whale Imaging underwent a strategic revitalization in 2008 under the leadership of Sean Zhu.

MENET is a platform for skilled information services that combines market research for hospitals, retail stores, business channels, and online medical and health information services. Their primary service offerings include online information data retrieval via the Internet, including industry tool libraries, global research and development libraries, market pattern libraries, and medical device libraries, as well as offline interactive client - centric offerings like thorough research, market research, terminal monitoring, and strategy consulting.

Whale is a manufacturer specializing in multi-planar surgical imaging and portable diagnostic ultrasound products. The company develops imaging devices that utilize proprietary technologies and advanced manufacturing methods to create safe and efficient systems. These products are designed to enhance the capabilities of surgeons, allowing them to perform procedures with increased speed and ease. By focusing on innovation and user-friendly design, Whale aims to improve surgical outcomes and streamline diagnostic processes in the medical field.

Angel Group Holding Company, based in Chengdu, China, is a private entity founded in 2008 that focuses on the integration of medical resources and brand management within the Chinese healthcare sector. The company employs a strategic approach characterized by expansion in services and investment, particularly in the interventional medical field, aiming to establish a diversified regional healthcare brand chain. Notably, its flagship facility, Angel Maternity Hospital, has garnered recognition as a leading maternity hospital in China, achieving accreditation from the Joint Commission International. This hospital exemplifies the company's commitment to high-quality medical services, emphasizing integrity and innovation. Angel Group also boasts a skilled management team and experienced medical professionals, dedicated to enhancing healthcare delivery in mainland China while adhering to international standards.

ASG Eye Hospitals is a prominent chain of super-specialty eye hospitals operating across various cities in India. Founded by experts from AIIMS, New Delhi, the organization has expanded its reach in regions including North and North East India, Rajasthan, Uttar Pradesh, Madhya Pradesh, Chhattisgarh, Jharkhand, Bihar, and Assam. The hospital network offers comprehensive ophthalmic care, specializing in a wide array of ocular sub-specialties, such as cataracts, diabetic retinopathy, glaucoma, macular degeneration, and eye tumors. ASG Eye Hospitals is committed to providing advanced diagnosis, treatment, and surgical services utilizing cutting-edge technology. The institution prides itself on employing highly skilled and trained professionals, including world-class surgeons with extensive surgical experience and expertise, ensuring patients receive top-tier eye care to help them regain their vision.

EndoChoice is a medical technology company specializing in the design and commercialization of products and services for gastrointestinal (GI) care. Headquartered in Alpharetta, Georgia, EndoChoice offers a comprehensive range of products, including single-use devices, infection control solutions, diagnostics, and advanced imaging systems. The company's proprietary product portfolio features the Full Spectrum Endoscopy™ System, known as Fuse™, which includes colonoscopes and gastroscopes equipped with multiple imagers. This innovative system enables physicians to achieve a 330-degree field of view, significantly improving the detection of polyps compared to traditional endoscopes. With a direct sales organization serving over 2,000 customers in the United States and partnerships with 34 distributors globally, EndoChoice has established a strong presence in the market. Founded in 2008, the company experienced rapid growth and was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. before its acquisition by Boston Scientific in 2016.

Betta Pharmaceuticals, established in 2003, is a leading Chinese pharmaceutical company specializing in the research, development, manufacturing, and marketing of innovative medicines. Its primary focus is on treating severe diseases like malignant tumors, diabetes, and cardio-cerebrovascular diseases. Betta's flagship product, Icotinib Hydrochloride (Conmana), is a pioneering targeted anti-cancer drug developed in China, used for treating non-small-cell lung cancer. The company has a strong pipeline with over 20 new drug development projects and holds more than 100 authorized patents. Betta Pharmaceuticals is headquartered in Hangzhou, with additional facilities in Beijing, and employs nearly 1,000 people, including many returned PhD holders. It has successfully listed on the GEM of the Shenzhen Stock Exchange and has received numerous awards for its innovative work, including the First Prize of National Prize for Progress in Science and Technology.

EndoSpan Ltd., established in 2008 and headquartered in Herzliya, Israel, specializes in the design and development of innovative stent graft systems under the brand name NEXUS. The company focuses on minimally invasive endovascular repair solutions for aortic arch diseases, including aneurysms and dissections. Its portfolio includes the Endo-Vascular Aortic Aneurysm Repair (EVAR) system, which is tailored for both unilateral and percutaneous approaches. By offering differentiated aortic endografts, EndoSpan aims to address the specific needs of patients with aortic lesions, providing effective treatment options in an underserved clinical area. The company is currently in the pre-clinical stage of development and is backed by venture capital.

Koncen BioScience was founded by a group of Chinese who returned to the country after completing their educations overseas. This high-technology biomedical enterprise offers integrated research and development, along with manufacturing and marketing services, all focused on blood purification technologies and products.

Hinacom Software and Technology, Ltd. is a healthcare IT company specializing in medical imaging and information management solutions. Based in Beijing, China, the company offers its miPlatform, an integrated medical imaging suite that encompasses various components such as Enterprise PACS/RIS, Regional PACS, TeleMed/TeleRad, web-based 3D processing, clinical image-based conferencing, and mobile imaging systems. The Enterprise PACS/RIS system is designed with a browser/server architecture to enhance workflow management, while the Regional PACS system facilitates patient-centered collaboration for medical imaging services across multiple hospitals in a region. The TeleMed/TeleRad system enables image transmission, viewing, and conferencing within web environments. Hinacom's solutions are utilized by hospitals and teleradiology projects in China, as well as by radiologists and clinicians in the United States, Europe, and Southeast Asia. Founded in 2008, the company has established itself as a key player in the medical imaging industry.

Celon Laboratories Pvt. Ltd., established in 2001 and headquartered in Hyderabad, India, is a specialty generics company focused on research, development, manufacturing, and marketing of pharmaceutical products. Its portfolio includes branded and generic formulations in the niche therapy areas of oncology and critical care, serving markets in Asia, Africa, Latin America, and Eastern Europe. The company's product range comprises various dosage forms such as tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. Additionally, Celon offers contract research manufacturing services, including formulation development, lyophilization cycle development, quality control testing, stability studies, and regulatory support. As of 2020, Celon operates as a subsidiary of ZNZ Pharma 2 Ltd.

marketRx, founded in 2000 and based in Bridgewater, New Jersey, is a provider of analytics software specifically designed for pharmaceutical and biotechnology companies. With a workforce exceeding 350 employees across offices in the United States, Europe, and India, the company has established itself as a key player in the industry. marketRx's software platform enhances the effectiveness of sales and marketing initiatives for over 75 clients, including all of the top-20 pharmaceutical companies. To support its expanding client base, the company has opened regional offices in Doylestown, Pennsylvania, Scottsdale, Arizona, and Berkshire, UK. Additionally, marketRx India, a wholly owned subsidiary established in 2003, plays a crucial role in operations outside the U.S., collaborating with U.S. teams and serving clients in Europe and the Asia Pacific region.